Report cover image

DTaP and Tdap Vaccines Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 129 Pages
SKU # APRC20542634

Description

Summary

According to APO Research, the global DTaP and Tdap Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for DTaP and Tdap Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of DTaP and Tdap Vaccines include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines.

The report will help the DTaP and Tdap Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The DTaP and Tdap Vaccines market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global DTaP and Tdap Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

DTaP and Tdap Vaccines Segment by Company

Johnson & Johnson
Novartis AG
Lanzhou Institute of Biological Products Co., Ltd
Pfizer Inc
GlaxoSmithKline
AstraZeneca
Seqirus
Sanofi Pasteur
Protein Sciences Corporation
Merck Sharp & Dohme Corp
Emergent BioSolutions Inc
Astellas Pharma US, Inc
DTaP and Tdap Vaccines Segment by Type

Tdap
DTaP
Td
DTaP and Tdap Vaccines Segment by Application

Adult
Pediatric
DTaP and Tdap Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of DTaP and Tdap Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

129 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global DTaP and Tdap Vaccines Market Size (2020-2031)
2.2.2 Global DTaP and Tdap Vaccines Sales (2020-2031)
2.2.3 Global DTaP and Tdap Vaccines Market Average Price (2020-2031)
2.3 DTaP and Tdap Vaccines by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Tdap
2.3.3 DTaP
2.3.4 Td
2.4 DTaP and Tdap Vaccines by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Adult
2.4.3 Pediatric
3 Market Competitive Landscape by Manufacturers
3.1 Global DTaP and Tdap Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global DTaP and Tdap Vaccines Sales (W Units) of Manufacturers (2020-2025)
3.3 Global DTaP and Tdap Vaccines Revenue of Manufacturers (2020-2025)
3.4 Global DTaP and Tdap Vaccines Average Price by Manufacturers (2020-2025)
3.5 Global DTaP and Tdap Vaccines Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of DTaP and Tdap Vaccines, Product Type & Application
3.8 Global Manufacturers of DTaP and Tdap Vaccines, Established Date
3.9 Global DTaP and Tdap Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Johnson & Johnson
4.1.1 Johnson & Johnson Company Information
4.1.2 Johnson & Johnson Business Overview
4.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
4.1.5 Johnson & Johnson Recent Developments
4.2 Novartis AG
4.2.1 Novartis AG Company Information
4.2.2 Novartis AG Business Overview
4.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
4.2.5 Novartis AG Recent Developments
4.3 Lanzhou Institute of Biological Products Co., Ltd
4.3.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
4.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
4.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
4.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
4.4 Pfizer Inc
4.4.1 Pfizer Inc Company Information
4.4.2 Pfizer Inc Business Overview
4.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
4.4.5 Pfizer Inc Recent Developments
4.5 GlaxoSmithKline
4.5.1 GlaxoSmithKline Company Information
4.5.2 GlaxoSmithKline Business Overview
4.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
4.5.5 GlaxoSmithKline Recent Developments
4.6 AstraZeneca
4.6.1 AstraZeneca Company Information
4.6.2 AstraZeneca Business Overview
4.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
4.6.5 AstraZeneca Recent Developments
4.7 Seqirus
4.7.1 Seqirus Company Information
4.7.2 Seqirus Business Overview
4.7.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
4.7.5 Seqirus Recent Developments
4.8 Sanofi Pasteur
4.8.1 Sanofi Pasteur Company Information
4.8.2 Sanofi Pasteur Business Overview
4.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
4.8.5 Sanofi Pasteur Recent Developments
4.9 Protein Sciences Corporation
4.9.1 Protein Sciences Corporation Company Information
4.9.2 Protein Sciences Corporation Business Overview
4.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
4.9.5 Protein Sciences Corporation Recent Developments
4.10 Merck Sharp & Dohme Corp
4.10.1 Merck Sharp & Dohme Corp Company Information
4.10.2 Merck Sharp & Dohme Corp Business Overview
4.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
4.10.5 Merck Sharp & Dohme Corp Recent Developments
4.11 Emergent BioSolutions Inc
4.11.1 Emergent BioSolutions Inc Company Information
4.11.2 Emergent BioSolutions Inc Business Overview
4.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
4.11.5 Emergent BioSolutions Inc Recent Developments
4.12 Astellas Pharma US, Inc
4.12.1 Astellas Pharma US, Inc Company Information
4.12.2 Astellas Pharma US, Inc Business Overview
4.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
4.12.5 Astellas Pharma US, Inc Recent Developments
5 Global DTaP and Tdap Vaccines Market Scenario by Region
5.1 Global DTaP and Tdap Vaccines Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global DTaP and Tdap Vaccines Sales by Region: 2020-2031
5.2.1 Global DTaP and Tdap Vaccines Sales by Region: 2020-2025
5.2.2 Global DTaP and Tdap Vaccines Sales by Region: 2026-2031
5.3 Global DTaP and Tdap Vaccines Revenue by Region: 2020-2031
5.3.1 Global DTaP and Tdap Vaccines Revenue by Region: 2020-2025
5.3.2 Global DTaP and Tdap Vaccines Revenue by Region: 2026-2031
5.4 North America DTaP and Tdap Vaccines Market Facts & Figures by Country
5.4.1 North America DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America DTaP and Tdap Vaccines Sales by Country (2020-2031)
5.4.3 North America DTaP and Tdap Vaccines Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe DTaP and Tdap Vaccines Market Facts & Figures by Country
5.5.1 Europe DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe DTaP and Tdap Vaccines Sales by Country (2020-2031)
5.5.3 Europe DTaP and Tdap Vaccines Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific DTaP and Tdap Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific DTaP and Tdap Vaccines Sales by Country (2020-2031)
5.6.3 Asia Pacific DTaP and Tdap Vaccines Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America DTaP and Tdap Vaccines Market Facts & Figures by Country
5.7.1 South America DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America DTaP and Tdap Vaccines Sales by Country (2020-2031)
5.7.3 South America DTaP and Tdap Vaccines Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa DTaP and Tdap Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2020-2031)
5.8.3 Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global DTaP and Tdap Vaccines Sales by Type (2020-2031)
6.1.1 Global DTaP and Tdap Vaccines Sales by Type (2020-2031) & (W Units)
6.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2031)
6.2 Global DTaP and Tdap Vaccines Revenue by Type (2020-2031)
6.2.1 Global DTaP and Tdap Vaccines Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2031)
6.3 Global DTaP and Tdap Vaccines Price by Type (2020-2031)
7 Segment by Application
7.1 Global DTaP and Tdap Vaccines Sales by Application (2020-2031)
7.1.1 Global DTaP and Tdap Vaccines Sales by Application (2020-2031) & (W Units)
7.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Application (2020-2031)
7.2 Global DTaP and Tdap Vaccines Revenue by Application (2020-2031)
7.2.1 Global DTaP and Tdap Vaccines Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2031)
7.3 Global DTaP and Tdap Vaccines Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 DTaP and Tdap Vaccines Value Chain Analysis
8.1.1 DTaP and Tdap Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 DTaP and Tdap Vaccines Production Mode & Process
8.2 DTaP and Tdap Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 DTaP and Tdap Vaccines Distributors
8.2.3 DTaP and Tdap Vaccines Customers
9 Global DTaP and Tdap Vaccines Analyzing Market Dynamics
9.1 DTaP and Tdap Vaccines Industry Trends
9.2 DTaP and Tdap Vaccines Industry Drivers
9.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
9.4 DTaP and Tdap Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global DTaP and Tdap Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global DTaP and Tdap Vaccines Sales (W Units) of Manufacturers (2020-2025)
Table 7. Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers (2020-2025)
Table 8. Global DTaP and Tdap Vaccines Revenue of Manufacturers (2020-2025)
Table 9. Global DTaP and Tdap Vaccines Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market DTaP and Tdap Vaccines Average Price (US$/Unit) of Manufacturers (2020-2025)
Table 11. Global DTaP and Tdap Vaccines Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of DTaP and Tdap Vaccines, Product Type & Application
Table 14. Global DTaP and Tdap Vaccines Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global DTaP and Tdap Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Johnson & Johnson Company Information
Table 19. Johnson & Johnson Business Overview
Table 20. Johnson & Johnson DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 21. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
Table 22. Johnson & Johnson Recent Developments
Table 23. Novartis AG Company Information
Table 24. Novartis AG Business Overview
Table 25. Novartis AG DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 26. Novartis AG DTaP and Tdap Vaccines Product Portfolio
Table 27. Novartis AG Recent Developments
Table 28. Lanzhou Institute of Biological Products Co., Ltd Company Information
Table 29. Lanzhou Institute of Biological Products Co., Ltd Business Overview
Table 30. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 31. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
Table 32. Lanzhou Institute of Biological Products Co., Ltd Recent Developments
Table 33. Pfizer Inc Company Information
Table 34. Pfizer Inc Business Overview
Table 35. Pfizer Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 36. Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
Table 37. Pfizer Inc Recent Developments
Table 38. GlaxoSmithKline Company Information
Table 39. GlaxoSmithKline Business Overview
Table 40. GlaxoSmithKline DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 41. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
Table 42. GlaxoSmithKline Recent Developments
Table 43. AstraZeneca Company Information
Table 44. AstraZeneca Business Overview
Table 45. AstraZeneca DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 46. AstraZeneca DTaP and Tdap Vaccines Product Portfolio
Table 47. AstraZeneca Recent Developments
Table 48. Seqirus Company Information
Table 49. Seqirus Business Overview
Table 50. Seqirus DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 51. Seqirus DTaP and Tdap Vaccines Product Portfolio
Table 52. Seqirus Recent Developments
Table 53. Sanofi Pasteur Company Information
Table 54. Sanofi Pasteur Business Overview
Table 55. Sanofi Pasteur DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 56. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
Table 57. Sanofi Pasteur Recent Developments
Table 58. Protein Sciences Corporation Company Information
Table 59. Protein Sciences Corporation Business Overview
Table 60. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 61. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
Table 62. Protein Sciences Corporation Recent Developments
Table 63. Merck Sharp & Dohme Corp Company Information
Table 64. Merck Sharp & Dohme Corp Business Overview
Table 65. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 66. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
Table 67. Merck Sharp & Dohme Corp Recent Developments
Table 68. Emergent BioSolutions Inc Company Information
Table 69. Emergent BioSolutions Inc Business Overview
Table 70. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 71. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
Table 72. Emergent BioSolutions Inc Recent Developments
Table 73. Astellas Pharma US, Inc Company Information
Table 74. Astellas Pharma US, Inc Business Overview
Table 75. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
Table 77. Astellas Pharma US, Inc Recent Developments
Table 78. Global DTaP and Tdap Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 79. Global DTaP and Tdap Vaccines Sales by Region (2020-2025) & (W Units)
Table 80. Global DTaP and Tdap Vaccines Sales Market Share by Region (2020-2025)
Table 81. Global DTaP and Tdap Vaccines Sales by Region (2026-2031) & (W Units)
Table 82. Global DTaP and Tdap Vaccines Sales Market Share by Region (2026-2031)
Table 83. Global DTaP and Tdap Vaccines Revenue by Region (2020-2025) & (US$ Million)
Table 84. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2020-2025)
Table 85. Global DTaP and Tdap Vaccines Revenue by Region (2026-2031) & (US$ Million)
Table 86. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2026-2031)
Table 87. North America DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 88. North America DTaP and Tdap Vaccines Sales by Country (2020-2025) & (W Units)
Table 89. North America DTaP and Tdap Vaccines Sales by Country (2026-2031) & (W Units)
Table 90. North America DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 91. North America DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 92. Europe DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 93. Europe DTaP and Tdap Vaccines Sales by Country (2020-2025) & (W Units)
Table 94. Europe DTaP and Tdap Vaccines Sales by Country (2026-2031) & (W Units)
Table 95. Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 96. Europe DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 97. Asia Pacific DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 98. Asia Pacific DTaP and Tdap Vaccines Sales by Country (2020-2025) & (W Units)
Table 99. Asia Pacific DTaP and Tdap Vaccines Sales by Country (2026-2031) & (W Units)
Table 100. Asia Pacific DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 101. Asia Pacific DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 102. South America DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 103. South America DTaP and Tdap Vaccines Sales by Country (2020-2025) & (W Units)
Table 104. South America DTaP and Tdap Vaccines Sales by Country (2026-2031) & (W Units)
Table 105. South America DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 106. South America DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 107. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 108. Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2020-2025) & (W Units)
Table 109. Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2026-2031) & (W Units)
Table 110. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 111. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 112. Global DTaP and Tdap Vaccines Sales by Type (2020-2025) & (W Units)
Table 113. Global DTaP and Tdap Vaccines Sales by Type (2026-2031) & (W Units)
Table 114. Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Table 115. Global DTaP and Tdap Vaccines Sales Market Share by Type (2026-2031)
Table 116. Global DTaP and Tdap Vaccines Revenue by Type (2020-2025) & (US$ Million)
Table 117. Global DTaP and Tdap Vaccines Revenue by Type (2026-2031) & (US$ Million)
Table 118. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)
Table 119. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2026-2031)
Table 120. Global DTaP and Tdap Vaccines Price by Type (2020-2025) & (US$/Unit)
Table 121. Global DTaP and Tdap Vaccines Price by Type (2026-2031) & (US$/Unit)
Table 122. Global DTaP and Tdap Vaccines Sales by Application (2020-2025) & (W Units)
Table 123. Global DTaP and Tdap Vaccines Sales by Application (2026-2031) & (W Units)
Table 124. Global DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Table 125. Global DTaP and Tdap Vaccines Sales Market Share by Application (2026-2031)
Table 126. Global DTaP and Tdap Vaccines Revenue by Application (2020-2025) & (US$ Million)
Table 127. Global DTaP and Tdap Vaccines Revenue by Application (2026-2031) & (US$ Million)
Table 128. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2025)
Table 129. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2026-2031)
Table 130. Global DTaP and Tdap Vaccines Price by Application (2020-2025) & (US$/Unit)
Table 131. Global DTaP and Tdap Vaccines Price by Application (2026-2031) & (US$/Unit)
Table 132. Key Raw Materials
Table 133. Raw Materials Key Suppliers
Table 134. DTaP and Tdap Vaccines Distributors List
Table 135. DTaP and Tdap Vaccines Customers List
Table 136. DTaP and Tdap Vaccines Industry Trends
Table 137. DTaP and Tdap Vaccines Industry Drivers
Table 138. DTaP and Tdap Vaccines Industry Restraints
Table 139. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. DTaP and Tdap Vaccines Product Image
Figure 5. Global DTaP and Tdap Vaccines Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global DTaP and Tdap Vaccines Market Size (2020-2031) & (US$ Million)
Figure 7. Global DTaP and Tdap Vaccines Sales (2020-2031) & (W Units)
Figure 8. Global DTaP and Tdap Vaccines Average Price (US$/Unit) & (2020-2031)
Figure 9. Tdap Product Image
Figure 10. DTaP Product Image
Figure 11. Td Product Image
Figure 12. Adult Product Image
Figure 13. Pediatric Product Image
Figure 14. Global DTaP and Tdap Vaccines Revenue Share by Manufacturers in 2024
Figure 15. Global Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters
Figure 16. Global Top 5 and 10 DTaP and Tdap Vaccines Players Market Share by Revenue in 2024
Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 18. Global DTaP and Tdap Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 19. Global DTaP and Tdap Vaccines Sales by Region in 2024
Figure 20. Global DTaP and Tdap Vaccines Revenue by Region in 2024
Figure 21. North America DTaP and Tdap Vaccines Market Size by Country in 2024
Figure 22. North America DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)
Figure 23. North America DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)
Figure 24. United States DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe DTaP and Tdap Vaccines Market Size by Country in 2024
Figure 27. Europe DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)
Figure 28. Europe DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)
Figure 29. Germany DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Netherlands DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Nordic Countries DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific DTaP and Tdap Vaccines Market Size by Country in 2024
Figure 36. Asia Pacific DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)
Figure 37. Asia Pacific DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)
Figure 38. China DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. South America DTaP and Tdap Vaccines Market Size by Country in 2024
Figure 47. South America DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)
Figure 48. South America DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)
Figure 49. Mexico DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa DTaP and Tdap Vaccines Market Size by Country in 2024
Figure 53. Middle East and Africa DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)
Figure 54. Middle East and Africa DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)
Figure 55. Turkey DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. UAE DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2031)
Figure 59. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2031)
Figure 60. Global DTaP and Tdap Vaccines Price (US$/Unit) by Type (2020-2031)
Figure 61. Global DTaP and Tdap Vaccines Sales Market Share by Application (2020-2031)
Figure 62. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2031)
Figure 63. Global DTaP and Tdap Vaccines Price (US$/Unit) by Application (2020-2031)
Figure 64. DTaP and Tdap Vaccines Value Chain
Figure 65. DTaP and Tdap Vaccines Production Mode & Process
Figure 66. Direct Comparison with Distribution Share
Figure 67. Distributors Profiles
Figure 68. DTaP and Tdap Vaccines Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.